{"prompt": "['MC1752', '42', 'OR', '(2) use (or have their partner use) acceptable contraception during heterosexual activity. Use in', 'Pregnancy', 'If a patient inadvertently becomes pregnant while on treatment with avelumab, the patient will', 'immediately be removed from the study. The site will contact the patient at least monthly and', \"document the patient's status until the pregnancy has been completed or terminated. The outcome\", 'of the pregnancy will be reported to Mayo Clinic and to EMD Serono without delay and within', '24 hours to Mayo Clinic and within 2 working days to EMD Serono if the outcome is a serious', 'adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life-', 'threatening complication to the mother or newborn).', 'The study investigator will make every effort to obtain permission to follow the outcome of the', 'pregnancy and report the condition of the fetus or newborn. If a male subject impregnates his', 'female partner the study personnel at the site must be informed immediately and the pregnancy', 'reported to Mayo Clinic and to EMD Serono and followed as described above.', '9.9c', 'Use in Nursing Adults', 'Since many drugs are excreted in human milk, and because of the potential for serious adverse', 'reactions in the nursing infant, patients who are breast-feeding are not eligible for enrollment.', 'Specific additional information follows for individual agents used in this trial.', '9.9c1 Avelumab', 'It is unknown whether avelumab is excreted in human milk. It is recommend that nursing', 'mothers not to breast feed for at least one month after final dose.', '9.9c2 Chemotherapy', 'Cisplatin has been reported to be found in human milk; patients receiving cisplatin', 'injection should not breast-feed. It is not known if fluorouracil is present in breast milk.', 'Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer', 'recommends a decision be made to discontinue breastfeeding or to discontinue', 'fluorouracil, taking into account the importance of treatment to the mother.', 'It is not known if mitomycin is present in breast milk. Due to the potential for serious', 'adverse reactions in the breastfed infant, breastfeeding is not recommended by the', 'manufacturer.', 'Table 6. Pretreatment Medication', 'Agent', 'Dose', 'Route', 'Day', 'Prior to weekly cisplatin infusions', 'DXM', '4mg', 'IV or PO', 'Emend', '150 mg', 'IV', 'Prior to weekly Cisplatin', 'infusions', 'Palonosetron', '0.25mg', 'IV', 'Prior to weekly Cisplatin', 'infusions', 'Ondansetron', '8 mg', 'IV', 'C3D1 (Day 29) of Mitomycin +', '5-FU infusion', 'Prochlorperazine', '10 mg', 'PO', 'Prior to 5-FU infusion (~Day 50)', 'Protocol Version Date: 21JUN2018']['MC1752', '43', '10.0', 'Adverse Event (AE) Monitoring and Reporting', 'The site principal investigator is responsible for reporting any/all serious adverse events to the sponsor as', 'described within the protocol, regardless of attribution to study agent or treatment procedure.', 'The sponsor/sponsor-investigator is responsible for notifying FDA and all participating investigators in a', 'written safety report of any of the following:', 'Any suspected adverse reaction that is both serious and unexpected.', 'Any findings from laboratory animal or in vitro testing that suggest a significant risk for human', 'subjects, including reports of mutagenicity, teratogenicity, or carcinogenicity.', 'Any findings from epidemiological studies, pooled analysis of multiple studies, or clinical', 'studies, whether or not conducted under an IND and whether or not conducted by the sponsor,', 'that suggest a significant risk in humans exposed to the drug', 'Any clinically important increase in the rate of a serious suspected adverse reaction over the rate', \"stated in the protocol or Investigator's Brochure (IB).\", 'Summary of SAE Reporting for this study', '(please read entire section for specific instructions):', 'WHO:', 'WHAT form:', 'WHERE to send:', 'Mayo Sites - attach to MCCC', 'Electronic SAE Reporting Form', 'Pregnancy Reporting', 'All sites', 'http://ctep.cancer.gov/protocolDevelopment/electronic a', 'Will automatically be sent', 'pplications/docs/PregnancyReportFormUpdated.pdf', 'to', 'Non Mayo sites - complete and', 'forward', 'to', 'Mayo Clinic Cancer Center SAE Reporting Form:', 'Will automatically be sent', 'Mayo Clinic', 'to', 'Sites', 'Mayo Clinic Cancer Center SAE Reporting', 'Form:', 'Will automatically be sent', 'Mayo Clinic', 'to', 'Sites', 'AND attach', 'MedWatch 3500A:', 'http://www.fda.gov/downloads/AboutFDA/ReportsMal', 'nualsForms/Forms/UCM048334.pdf', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}